Merck-Singapore Drug Discovery and Translational Medicine Inaugural Symposium

Day 1: Tuesday, March 3 2015, Biopolis Matrix Level 4

Time	Event
8:00am-9:00am	Registration/poster setup
9:00am-9:15am	Introductory Welcome – *Jonathan Kua (BMS IPO)* Opening Remarks – *Guest-of-honor Mr Lim Chuan Poh, Chairman, A*STAR* Announcements – *Bing Lim (Merck)*
9:15am-10:00am	The Keytruda Story *Rob Kastelein (Merck)*
10:00am-10:45am	Drug Discovery in Singapore *David Lane (A*STAR)*
10:45am-11:15am	Coffee break, visit posters
11:15am-11:45am	Case study: Suvorexant – Discovery to Approval *John Renger (Merck)*
11:45pm-12:15pm	Case study: Curing HCV by Combination Targeted Therapy *Wade Blair (Merck)*
12:15pm-1:30pm	Lunch, visit posters
1:30pm-2:00pm	Vaccine R&D at MRL *Danilo Casimiro (Merck)*

2:00pm-2:45pm	Drug Discovery Projects
	  i. Beyond Biomarker: Immunomonitoring as a Lead for Target Discovery – *John Connolly (IMCB)*
	  ii. Genetic Target in Diabetes –*E-Shyong Tai (NUH)*

2:45pm-3:00pm	Coffee break, visit posters

3:00pm-3:45pm	Drug Discovery Projects
	  i. Multi-dimensional Single Cell Analysis - *Evan Newell (SIgN)*
	  ii. Directed Differentiation and Characterization of Microglial Precursors from Pluripotent Stem Cells – *Florent Ginhoux (SIgN)*

3:45pm-4:15pm	Drug Development – BACE-Inhibitor Against Alzheimer's Disease. *Matt Kennedy (Merck)*
4:15pm-4:45pm	Merck-Singapore Collaboration Vision *Robert Plenge (Merck)*
4:45pm-5:00pm	Closing remarks *Bing Lim (Merck), Jonathan Kua (BMS IPO)*
5:00pm-7:00pm	Visit posters, networking, reception

Day 2: Wednesday, March 4 2015, Biopolis Matrix Level 5 Multifunction Rooms 1 & 2

Time	Event	
WORKSHOPS – Registration required		
Time	**Event**	
07:30am-9:00am	Networking breakfast	
9:00am-10:00am	**Drug Discovery I**	**Translational Medicine I**
	• Functional Validation of Drug Targets Identified Through Genetics – *Michele Cleary (Merck)* • Target Identification by Large Scale Mapping of Chromatin Altering Polymorphism – *Shyam Prabhaker (GIS)* • Targeting Novel Pathways in Cancers – *Ronan O'Hagan (Merck)* • Pharmacogenomics of Adverse Drug Reaction -*JJ Liu (GIS)*	• Biomarker Discovery in Drug Development – *Shian-Jiun Shih (Merck)* • Imaging in Drug Development – *Chih-Liang Chin (Merck)* • Patient Stratification by Genetics -The Singapore Polaris Program – *Patrick Tan (GIS/Duke-NUS)*
10:00am-10:30am	Panel Q&A: *Michelle Cleary (Merck), Shyam Prabhaker (GIS), Ronan O'Hagan (Merck), JJ Liu (GIS)*	Panel Q&A: *Shian-Jiun Shih (Merck), Chih Liang Chin (Merck), Patrick Tan (GIS/DUKE NUS)*
10:30am-11:00am	Coffee Break	
11:00am-12:00pm	**Drug Discovery II**	**Translational Medicine II**
	• Identification of tool molecules to aid target validation and new drug discovery programs – Dr. Brian Henry (Merck) • Advances in the identification of lead molecules – Dr. Brian Dymock (NUS) • Progressing hits to clinical candidates – Dr. Jonathan Bennett (Merck)	• Clinical Studies in an Industrial Setting – *Manu Chakravarthy (Merck)* • Discovery Medicine from Academic- Industry Collaboration – *Khoo Chin Meng (NUS)* • Translational Studies in NUS/NUH – *Goh Boon Cher (NUS/NUHS)* • Investigator-Led Clinical trials in NCCS – *Toh Han Chong (NCCS)*
12:00pm-12:30pm	Panel Q&A: *Brian Henry (Merck), Brian Dymock (NUS), Jonathan Bennett (Merck)*	Panel Q&A: *Manu Chakravarthy (Merck), Inge De Lepeleire (Merck), Khoo Chin Meng (NUS), Goh Boon Cher (NUS/NUHS), Toh Han Chong (NCCS)*